| Autor: |
Segec, A, Keller‐Stanislawski, B, Vermeer, NS, Macchiarulo, C, Straus, SM, Hidalgo‐Simon, A, De Bruin, ML |
| Předmět: |
|
| Zdroj: |
Clinical Pharmacology & Therapeutics; Nov2015, Vol. 98 Issue 5, p502-505, 4p |
| Abstrakt: |
Progressive multifocal leukoencephalopathy (PML) has been observed after the use of several medicines, including monoclonal antibodies. As these drugs play important roles in the therapeutic armamentarium, it is important to address the challenges that this severe adverse reaction poses to the safe use of medicines. Considering the need for consistent outcomes of regulatory decisions, the European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) used PML as an example to develop a systematic approach to labeling and risk minimization. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text